BioSyent to Present at the 2014 Bloom Burton & Co. Healthcare Investor Conference
June 13 2014 - 5:12PM
Marketwired
BioSyent to Present at the 2014 Bloom Burton & Co. Healthcare
Investor Conference
TORONTO, ONTARIO--(Marketwired - Jun 13, 2014) - BioSyent Inc.
("BioSyent") (TSX-VENTURE:RX) is pleased to announce that CEO René
Goehrum will be making a presentation at the 2014 Bloom Burton
& Co. Healthcare Investor Conference at 4:30pm (ET), June 18,
2014 at the Toronto Board of Trade. Mr. Goehrum will provide an
overview of the Company and its corporate activities.
Mr. Goehrum will be available for 1:1 meetings on the day of his
presentation.These meetings can be arranged via the conference
organizers http://www.bloomburton.com/conference/.
BioSyent also announces the grant of 17,031 incentive stock
options to certain employees and officers of the Company. These
incentive stock options are exercisable at a price of $7.45 up to
June 12, 2024.
For a direct market quote (15 minutes delay) for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol
"RX", BioSyent is a profitable growth oriented specialty
pharmaceutical company which searches the globe to in-license or
acquire innovative pharmaceutical products that have been
successfully developed, are safe and effective, and have a proven
track record of improving the lives of patients and supporting the
healthcare professionals that treat them.
Once a product of interest has been found, BioSyent then
acquires the exclusive rights to the product and manages it through
the Canadian governmental regulatory approval process. Once
approved, BioSyent markets the product throughout Canada.
At the date of this press release the Company had 13,801,195
shares issued and outstanding.
Mr. Rene C. GoehrumPresident and CEOBioSyent Inc.Tel: (905)
206-0013investors@biosyent.comwww.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2024 to May 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From May 2023 to May 2024